Back to Authors

Soefje, Scott A

0000-0002-5486-7748

Mayo Clinic

Mayo Clinic

Citations 14

Decreasing drug waste, reducing drug costs, and improving workflow efficiency through the implementation of automated chemotherapy dose rounding rules in the electronic health record system
Shah, Vishal , Spence, A, Bartels, Trace , Betcher, Jeffrey, Soefje, Scott A. , Soefje, Scott A , Shah, Vishal

American Journal of Health-System Pharmacy | December 23, 2021 | Volume: 79 | Issue: 8 | Pages: 676-682

10.1093/ajhp/zxab479 Get It

Abstract Purpose To decrease drug waste and cost by implementing automated chemotherapy dose rounding rules in the electronic health record (EHR). Dose rounding of chemotherapy is a recognized method for reducing drug waste, and professional organizations have published guidelines recommending dose rounding when possible. Summary On the basis of current literature and guideline recommendations, Mayo Clinic developed system-wide consensus to allow dose rounding for biologic and chemotherapy agents to the nearest vial size if rounding resulted in the dose being within 10% of the originally calculated dose or to a convenient measurable volume, based on concentration of the drug, if rounding to the nearest vial size resulted in the dose being outside the 10% range. Oncology pharmacists reviewed and analyzed all drugs listed in the EHR used in injectable form for the treatment of cancer and developed dose rounding rules. The rules were implemented and applied at the dose calculation stage before provider signature. From January to June 2019, approximately 40,000 cancer treatment doses were administered. The rounding rules saved a total of 9,814 vials of drug, of which 5,329 were for biologic agents and 4,485 were for oncolytic drugs. This resulted in a total 6-month cost savings of $7,284,796 (in 2019 dollars; biologics, $5,727,402; oncolytics, $1,557,394). Conclusion Systematic implementation of dose rounding rules utilizing the EHR can result in significant reduction of drug waste and realization of savings.
Evaluation of Burnout in a National Sample of Hematology-Oncology Pharmacists
Golbach, Allison P. , McCullough, Kristen , Soefje, Scott A. , Mara, Kristin C. , Shanafelt, Tait D. , Merten, Julianna A., McCullough, Kristen B , Shanafelt, Tait D , Mara, Kristin C , Soefje, Scott A , Golbach, Allison P. , Merten, Julianna A.

JCO Oncology Practice | November 18, 2021 | Volume: 18 | Issue: 8 | Pages: e1278-e1288

10.1200/op.21.00471 Get It

PURPOSE: To evaluate the prevalence of burnout among hematology-oncology pharmacists and factors associated with an increased risk of high burnout. METHODS: Between October and November 2020, members of the Hematology/Oncology Pharmacy Association were invited to complete an anonymous survey. Questions included the Maslach Burnout Inventory (MBI), Well-Being Index, and sociodemographic and occupational factors linked with burnout. RESULTS: Of 3,024 pharmacists contacted, 614 pharmacists (20.3%) responded to an online survey and 550 (18.2% of overall sample) completed the MBI and were included for analysis. Overall, high levels of burnout were observed in 61.8% of respondents based on the MBI, with 57.9% of respondents scoring high on the emotional exhaustion domain and 31.3% high in the depersonalization domain. Pharmacists with burnout worked on average 48.6 (±9.6) hours per week compared with 44.5 (±9.6) hours per week for those without high burnout and spent more time on administrative tasks per week (7.5 hours v 4.3 hours; all P < .001). Pharmacists reporting high burnout were more likely to report concern they had made a major medication error within the past 3 months (27.6% v 8.1%; P < .001) and greater intent to leave their current job within 2 years (60.3% v 19.0%; P < .001). CONCLUSION: Burnout is prevalent among hematology-oncology pharmacists and may affect both patient safety and the adequacy of the workforce. Risk factors for burnout among hematology-oncology pharmacists in this study may be targets for burnout mitigation and prevention strategies to reduce the impact on pharmacists and improve cancer care for patients.
Development of an innovative delivery system for bacillus Calmette-Guérin bladder administration
Szewczyk, Michael T, Soefje, Scott A. , Soefje, Scott A

American Journal of Health-System Pharmacy | October 22, 2020 | Volume: 78 | Issue: 1 | Pages: 60-64

10.1093/ajhp/zxaa339 Get It

Abstract Purpose To describe the development of an innovative process to deliver bacillus Calmette-Guérin (BCG) to an offsite urology clinic for bladder instillation. Summary The use of BCG, a live virus vaccine for treatment of patients with localized cancer of the urinary bladder, has created many logistical problems for hospitals and infusion center pharmacies. Due to its short stability, the drug cannot be made ahead of time and coordination with a patient’s arrival at an infusion site is challenging. This becomes exceptionally challenging when a urology clinic has limited compounding capacity and/or is distant from the site of BCG medication preparation. This article describes an innovative process involving use of closed-system transfer devices (CSTDs) to allow for the administration of BCG in a urology clinic offsite from a medical center’s infusion center facilities. Conclusion The use of the CSTD allowed the patients to continue to receive bladder instillations at an offsite urology clinic without significantly disrupting compounding workflow at the small infusion center pharmacy that was the nearest to the clinic.
PRN OPINION PAPER: Application of precision medicine across pharmacy specialty areas
Caudle, Kelly E. , Gammal, Roseann S., Karnes, Jason H. , Afanasjeva, Janna, Anderson, Keri C. , Frazee, Erin N. , Beavers, C. , Bhat, Shubha , Birrer, Kara L., Ensor, Christopher R. , Flowers, Stephanie A. , Formea, Christine M. , George, Jomy, Gosser, Rena , Karaoui, Lamis R. , Kolpek, Jimmi Hatton , Leung, Jonathan G. , Maldonado, Angela Q. , Minze, Molly G. , Pulk, Rebecca , Shelton, Chasity M. , Sheridan, Maria , Smith, Michael A. , Soefje, Scott A. , Tellez‐Corrales, Eglis , Walko, Christine M. , Leung, Jonathan G , Soefje, Scott A , Chahine, Elias B. , Hébert, Mary F. , Lee, James C. , Sheridan, Maria, Cavallari, Larisa H.

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | March 25, 2019 | Volume: 2 | Issue: 3 | Pages: 288-302

10.1002/jac5.1107 Get It

Clinical pharmacists have been incorporating precision medicine into practice for decades. Drug selection and dosing based on patient‐specific clinical factors such as age, weight, renal function, drug interactions, plasma drug concentrations, and diet are expected as part of routine clinical practice. Newer concepts of precision medicine such as pharmacogenomics have recently been implemented into clinical care, while other concepts such as epigenetics and pharmacomicrobiomics still predominantly exist in the research area but clinical translation is expected in the future. The purpose of this paper is to describe current and emerging aspects of precision medicine as it relates to clinical pharmacy across a variety of specialty areas of practice, with perspectives from the American College of Clinical Pharmacy Practice and Research Network membership.